Maxim Group Reiterates “Hold” Rating for Cyclo Therapeutics (NASDAQ:CYTH)

Maxim Group reissued their hold rating on shares of Cyclo Therapeutics (NASDAQ:CYTH) in a research note released on Tuesday morning, MarketBeat Ratings reports.

Other analysts have also issued research reports about the company. Ascendiant Capital Markets dropped their target price on Cyclo Therapeutics from $2.60 to $0.95 and set a buy rating on the stock in a report on Monday, August 26th. HC Wainwright reissued a neutral rating and issued a $0.95 target price (down from $3.00) on shares of Cyclo Therapeutics in a research note on Friday, August 23rd.

Cyclo Therapeutics Stock Performance

NASDAQ CYTH opened at $0.75 on Tuesday. The stock has a market capitalization of $21.40 million, a price-to-earnings ratio of -0.75 and a beta of -0.33. Cyclo Therapeutics has a 52 week low of $0.70 and a 52 week high of $2.12. The stock’s 50 day moving average price is $1.15 and its two-hundred day moving average price is $1.33.

Cyclo Therapeutics (NASDAQ:CYTH) last released its earnings results on Thursday, August 15th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07). Cyclo Therapeutics had a negative net margin of 1,720.76% and a negative return on equity of 2,741.89%. The business had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.40 million. On average, equities research analysts forecast that Cyclo Therapeutics will post -0.62 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cyclo Therapeutics stock. Founders Fund VI Management LLC bought a new position in shares of Cyclo Therapeutics, Inc. (NASDAQ:CYTH) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 110,023 shares of the company’s stock, valued at approximately $175,000. Cyclo Therapeutics makes up about 1.4% of Founders Fund VI Management LLC’s investment portfolio, making the stock its 2nd biggest position. Founders Fund VI Management LLC owned 0.48% of Cyclo Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 68.55% of the company’s stock.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.